You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 16, 2025

Claims for Patent: 12,285,430

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 12,285,430

Title:	Methods of treating disorders using CSF1R inhibitors
Abstract:	Described herein are methods of treating cancers and other tumors related to the decreased proliferation, the depletion, or the repolarization of tumor-associated macrophages (TAMs) and treatment of associated disorders, including tenosynovial giant cell tumor (TGCT) and diffuse-type tenosynovial giant cell tumor (DTGCT).
Inventor(s):	Daniel L. Flynn, Bryan D. Smith, Rodrigo Ruiz Soto, Keisuke Kuida
Assignee:	Deciphera Pharmaceuticals LLC
Application Number:	US18/140,942
Patent Claims:	1. A method of treating a tenosynovial giant cell tumor in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound represented by: wherein after 1 month or more of administration, the patient has: (i) an improved tumor response as measured by CT, MRI and/or RECIST; and/or (ii) an improved range of motion; and/or (iii) reduced macrophage infiltration in the affected joint and/or circulating chemokine/cytokines associated with inflammation as compared to the amounts before administration. 2. The method of claim 1, wherein the tumor is benign. 3. The method of claim 1, wherein the tenosynovial giant cell tumor is a diffuse-type tenosynovial giant cell tumor. 4. The method of claim 1, wherein the therapeutically effective amount is about 2 mg to about 60 mg of the compound twice weekly. 5. The method of claim 1, wherein the therapeutically effective amount is about 5 mg to about 30 mg of the compound twice weekly. 6. The method of claim 1, comprising administering to the patient the compound twice weekly for about 3 months. 7. The method of claim 1, comprising administering to the patient the compound twice weekly for about 6 months. 8. The method of claim 1, comprising administering to the patient the compound twice weekly for about 1 year. 9. The method of claim 1, comprising administering to the patient the compound twice weekly for about 2 years. 10. A method of treating a tenosynovial giant cell tumor in a patient in need thereof, comprising administering to the patient 30 mg of a compound represented by: twice weekly, wherein after 1 month or more of administration, the patient has: (i) an improved tumor response as measured by CT, MRI and/or RECIST; and/or (ii) an improved range of motion; and/or (iii) reduced macrophage infiltration in the affected joint and/or circulating chemokine/cytokines associated with inflammation as compared to the amounts before administration. 11. The method of claim 10, wherein the tumor is benign. 12. The method of claim 10, wherein the tenosynovial giant cell tumor is a diffuse-type tenosynovial giant cell tumor. 13. The method of claim 10, comprising administering to the patient the compound twice weekly for about 3 months. 14. The method of claim 10, comprising administering to the patient the compound twice weekly for about 6 months. 15. The method of claim 10, comprising administering to the patient the compound twice weekly for about 1 year. 16. The method of claim 10, comprising administering to the patient the compound twice weekly for about 2 years. 17. A method of treating a tenosynovial giant cell tumor in a patient in need thereof, comprising administering to the patient 30 mg of a compound represented by: 18. A method of treating a tenosynovial giant cell tumor in a patient in need thereof, comprising daily administering to the patient 50 mg of a compound represented by:

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.